References
- Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J. 2006;27:397–412.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
- Global strategy for diagnosis, management, and prevention of COPD. Available at: http://www.goldcopd.com/Guidelineitem.asp?l12&l21&intId 2003. Accessed Mar 2, 2010.
- DiMatteo MR. Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Med Care. 2004;42:200–209.
- Rand CS. Non-adherence with asthma therapy: More than just forgetting. J Pediatr. 2005;146:157–159.
- World Health Organization. Adherence to long-term therapies: Policy for action. Meeting report 2001 Jun 4–5. Available at: http://www.who.int/chronic_conditions/adherence/en/. Accessed Jul 29, 2010.
- Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008; 63:831–838.
- Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14:775–783.
- Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007;29:575–581.
- Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29:871–878.
- Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007;20:740–749.
- Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033–1044.
- Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338.
- Bauwens O, Ninane V, van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: Comparison with placebo and formoterol. Curr Med Res Opin. 2009; 25:463–470.
- Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14:25–29.
- Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–124.
- Santus P, Matera MG, Carlucci P, et al. Onset of action of salmeterol/fluticasone (SFC) in single inhaler vs salmeterol (S) in patients with COPD. Eur Respir J. 2003;22 Suppl:285.